Format

Send to

Choose Destination
Cancer Immunol Immunother. 2016 Sep;65(9):1099-111. doi: 10.1007/s00262-016-1872-z. Epub 2016 Jul 22.

Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis.

Author information

1
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
2
R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
3
Seren Clinic Fukuoka, Fukuoka, 810-0001, Japan.
4
Cell Processing Center, Shinshu University Hospital, Matsumoto, Nagano, 390-8621, Japan.
5
Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Hokkaido, 003-0006, Japan.
6
Seren Clinic Nagoya, Nagoya, Aichi, 460-0008, Japan.
7
Seren Clinic Kobe, Kobe, Hyogo, 650-0001, Japan.
8
Seren Clinic Tokyo, Tokyo, 108-0071, Japan.
9
Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
10
Tottori University Hospital Cancer Center, Tottori, Yonago, 683-8504, Japan.
11
Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, 108-8641, Japan.
12
Division of Clinical Medicine, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, Tokyo, 108-8641, Japan.
13
R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. yonemitu@med.kyushu-u.ac.jp.

Abstract

OBJECTIVE:

The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers.

METHODS:

Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks.

RESULTS:

The mean survival time (MST) from diagnosis was 33.0 months (95 % confidence interval [CI]: 27.9-39.2), and that from time of first vaccination was 13.8 months (95 % CI 11.4-16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 %, respectively, P = 0.014).

CONCLUSIONS:

This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.

KEYWORDS:

Adenocarcinoma; Dendritic cell vaccine; Erythema; Non-small cell lung cancers

PMID:
27448677
DOI:
10.1007/s00262-016-1872-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center